

1 **Jefferson Office of Human Research**
2 **Informed Consent OHR-8**
3 **Version Date – FOR OHR USE: 5/22/20**
4

5 **Department:** Department of Internal Medicine/Division of Gastroenterology
6

7 **Principal Investigator:** Anand Kumar MD MPH
8

9 **Study Title:** Closure of mucosal and submucosal defects in the gastrointestinal tract using the
10 novel X-Tack endoscopic suturing device
11

12 **Lay Title:** Closure of defects with the X-Tack endoscopic suturing device
13

14 **General Information Section**
15

16 **Informed Consent**
17

18 You are being asked to take part in a research study. Research is different from standard
19 medical care, and is done to learn something new.
20

21 Please read on to find out:
22

- 23
- 24 • The purpose of this research.
 - 25 • How this research is different from standard medical care.
 - 26 • The procedures and the device involved.
 - 27 • The risks.
 - 28 • The possible benefits.
 - 29 • The alternatives to taking part in this research.

30 You will have the opportunity to discuss this study with the research personnel. Use this
31 information to decide if you want to take part in this research. This process is called informed
32 consent.
33

34 **Voluntary Participation**
35

36 You do not have to take part in this research. It is your choice whether or not you want to take
37 part. If you choose not to take part or choose to stop taking part at any time, there will be no
38 penalty or loss of benefits that you would normally get.
39

40 **Purpose**

41
42 The purpose of this research is to determine whether a new device for suturing in the
43 gastrointestinal tract is better (safer and more effective) than the current standard device for
44 suturing.

45
46 **How this Research is Different from Standard Medical Care**

47
48 The new device being examined in this study is FDA-cleared for the suturing of mucosal defects
49 (injury to the wall of the gastrointestinal tract left behind after a lesion is removed) or fistulas
50 (abnormal connections in the gastrointestinal tract,) but has not yet been compared to the
51 current standard device.

52
53 **Number of Participants**

54
55 About 50 people will take part in this research and Jefferson and about 50 in the whole study.

56
57 Inclusion criteria: Patients over 18 years of age who are having a defect closed with endoscopic
58 sutures (stiches.)

59 Exclusion criteria: Blood clotting disorders, use of blood thinner medications, low blood pressure
60 or fast heart rate, pregnancy

61
62 **Duration**

63
64 You will be in this research study during your procedure. You will receive a phone call 2-3 days
65 after your procedure. Your health information collected during the study will be stored
66 indefinitely.

67
68 **Procedures and Risks**

69
70 It is important that you know the procedures and risks involved in this research. These will be
71 discussed with you and are included in detail later in this form. Review the information carefully
72 when making your decision to take part in this research.

73
74 **Possible Benefits**

75
76 You may or may not personally benefit from taking part in this research, but the knowledge gained
77 from the research may benefit others.

78
79 **Alternatives to Taking Part in this Research**

80

81 You have other options than taking part in this study. The alternative to being in this study is to
82 not take part. This will not change your medical care, and your procedure will still be performed.

83

84 **Costs**

85

86 You may have costs for participating in this study. This is discussed in detail later in this form.

87

88 **Payment**

89

90 You will not be paid for taking part in this study. If this research or the information or specimens
91 you provide result in commercial profit, you will not receive any money from that profit.

92

93 **Ending Study Early**

94

95 There are a number of reasons you may decide or be asked to stop the study early (example:
96 medical issues). You may also have to stop the study early even if you do not want to. You and
97 the research personnel will discuss the reason if this becomes necessary. If you do leave the
98 study early, you may be asked to complete some of the procedures described in this form.

99

100 **New Information**

101

102 New information may come out during this study. You will be given any new information that
103 could change your decision to take part. You may ask to see the information collected about you,
104 but not until the entire study is complete. If in the future we learn information that will affect
105 your health at that point in time, you will be given any research results that could affect your
106 health. This is unlikely to happen.

107

108 **Detailed Information Section**

109

110 **Drugs/Devices**

111

112 The devices used in this study are described below:

113 Endoscope (flexible camera used to get to your lesion or fistula,) electrosurgical knife (a special
114 device with a small needle that conducts electricity and acts as a knife when activated,)
115 endoscopic clips (small metal clips placed with the endoscope used to close defects or holes that
116 dislodge on their own after several weeks,) electrosurgical snares (loops of wire that can conduct
117 an electrical current and are used to remove abnormal tissue,) Overstitch endoscopic suturing
118 device (a device that is mounted on the endoscope and allows your doctor to place stitches with
119 the endoscope.) All of the above devices are standard care. The study device is the X-Tack
120 endoscopic suturing device, which also allows your doctor to place stitches with an endoscope
121 but is mounted on the scope without having to remove it from the patient. You will either be

122 randomly assigned to the standard group or the X-Tack group. You are equally likely to be chosen
123 for either group.

124


125 **Procedures**

126

127 While you are in this study, you will have one of two techniques performed during your
128 endoscopy which are described below. During your endoscopy, you will be randomized to one
129 technique or the other. Please note that additional tests and procedures may be needed to check
130 on your health condition, including blood tests, imaging tests or additional endoscopic
131 procedures.

132

133



134

135 Name of procedure #1 (half of patients): Standard closure

136

137 Description: The endoscope will be advanced to a target site. When it is time to close the target
138 site, the endoscope will be removed and the Overstitch device will be mounted on the endoscope.
139 The endoscope will then be reintroduced. The Overstitch device will be used to place stitches
140 around the margins of the target site, and then the stitches will be cinched tight. After the defect
141 is closed, your doctor will inspect the area to make sure that the stitches are well-positioned.

142

143 Risks: Risks of closure with the Overstitch include failed closure of the target and very rarely
144 bleeding, infection, or a tear/perforation of the gastrointestinal tract.

145

146 Name of procedure #2 (half of patients): X-Tack closure

147

148 Description: The endoscope will be advanced to a target site. The X-Tack system will be
149 introduced through a channel in the endoscope. The X-Tack system will be used to close the
150 defect by applying tacks at the edges of the defect and then using a stitch to cinch them together.
151 After the defect is closed, your doctor will inspect the area to make sure that the tacks are well-
152 positioned. The tacks are designed to fall off after several weeks.

153

154 Risks: The risks of X-Tack closure are anticipated to be identical to those of Overstitch closure,
155 listed above, though the X-Tack device is newer and less data is available.

156

157 **Risks**

158
159 Taking part in this study involves certain risks. The risks are the risks of performing endoscopic
160 closure of a fistula or defect, whether or not you are participating in this study. Both the
161 techniques being studied are anticipated to have similar risks. There may also be risks that are
162 not known at this time. If you have any medical issues during this study, call the appropriate
163 number in the contacts section of this form.

164
165 Risks of endoscopic suturing using either the X-Tack or the Overstitch device include bleeding,
166 infection, perforation, or failure of closure of the target defect.

167
168 **Reproductive Risks**

169
170 Pregnant women are excluded from study participation.

171
172 **Costs**

173
174 You may have costs for participating in this study, though no additional costs are anticipated to
175 be associated with the study. We anticipate that your insurance will cover this device as part of
176 your procedure. There won't be any difference in costs whether you are in one study group of
177 the other. There won't be any difference in costs if you are in the study or not.

178
179 You may be responsible for other costs. There is no plan to pay you for lost wages, lost time from
180 work, personal discomfort, or for injuries or problems related to your underlying medical
181 condition(s). If you receive a bill that you think is wrong, please contact the research personnel.
182 You will be responsible to pay for your travel to and from the study site and other out-of-pocket
183 expenses such as parking.

184
185 **Research-Related Injury**

186
187 There is a possibility that you could have research-related injury, which is an illness or an injury
188 that is directly caused by the study device or a study procedure. If you have a research-related
189 injury, we will offer you reasonable and necessary care to treat injuries directly resulting from
190 taking part in this research. Neither Jefferson nor the study will pay for costs associated with
191 treatment of research-related injury or illness. These costs may be billed to your insurance. In
192 addition, you will be responsible for any deductibles and co-payments required under your health
193 plan and for any claims ultimately denied by your health plan. There are no plans for Jefferson to
194 pay you or give you other compensation for the injury. If you think you have been injured as a
195 result of taking part in this research study, tell the research personnel as soon as possible. Please
196 see the contact information in this consent form.

197

198 **Disclosure of Financial Interest**

199
200 The study group has no financial interest with the company that produces the study device. There
201 is no financial benefit either for the participant (you,) the investigators, or the institution.
202

203 **Privacy and Confidentiality: HIPAA Authorization**

204
205 Information will be collected about you for this study. The information will be seen by the people
206 involved with this research. Steps will be taken to protect your identity. But the information
207 collected about you can never be 100% secure.
208

209 HIPAA (Health Insurance Portability and Accountability Act) – This is the law that protects your
210 personal health information.

211
212 To do this study, we need to collect, use, and share your personal health information. This form
213 will explain why your information is being collected, what information will be collected, and who
214 will have access to it. By signing, you are giving us permission to use your information as described
215 in this form.

216
217 We are committed to respecting your privacy and to keeping your personal health information
218 confidential. Your personal health information includes the information in your health care
219 records and information that can identify you. For example, personal information may include
220 your name, address, phone number, social security number, and medical information. The
221 personal health information that may be collected, used, and shared for this research includes:

- 222
- 223 • Information from your medical records
 - 224 • Demographic information such as name, gender, birth date, ethnicity, medical history,
225 and health care providers
 - 226 • Physical examinations, procedures, tests, labs, your medical conditions, and medications
227 you use
 - 228 • Information collected about any research related injury
 - 229 • Information about mental health, sexually transmitted diseases, HIV, AIDS, drug and
230 alcohol use, genetic test results, and other sensitive information
 - 231 • Photos and video recordings from the study procedure
- 232

233 Your personal information will be used by and shared with the following:

- 234
- 235 • Personnel at Thomas Jefferson University and its affiliates for the purpose of this research
 - 236 • Institutional Review Boards (ethics committees that review research)
 - 237 • Health insurance providers

- 238 • Government Agencies like the Food and Drug Administration (FDA)
239 • Groups monitoring the safety of the study such as a data and safety monitoring committee
240 • Others as required by law
241

242 When your personal information is provided to some of the people listed, it may no longer be
243 protected under the HIPAA privacy law. You can see your health care records at any time.
244 However, generally you will not be able to see your study records or the study results until the
245 study is completed. A copy of this signed form, information about this study, and the results of
246 any study test or procedure may be included in your health records which may be seen by your
247 insurance company and your health care providers.
248

249 This authorization does not have an expiration date. Please inform the investigator in writing if
250 you want to end your permission to collect information/samples. Please note that anything
251 already collected will still be used and you may not be able to continue in this study.
252

253 The information from this study may be published in scientific journals or presented at scientific
254 meetings, but you will not be personally identified.
255

256 A description of this study will be available on <http://www.ClinicalTrials.gov>, as required by U.S.
257 Law. This website will not include information that can identify you. At most, the website will
258 include a summary of the results. You can search this website at any time.
259

260 **Contacts**

261
262 **If you are having a medical emergency, call 911 or go directly to an emergency room. You**
263 **should let emergency personnel or providers know that you are taking part in this study.**
264

For Questions About:	Person or Office	Contact Information
The Study or Research Related Injury	Main Investigator: Anand Kumar MD MPH	215-955-8900
If you need to contact someone other than the study personnel about a concern or your rights as a research subject	Jefferson Center City	215-503-0203
	Institutional Review Board (Ethics Committee)	215-503-8966
		215-955-4239

265
266

267 **Signatures**

268

269 Patient/Subject: By signing this form, you are agreeing that:

270

- 271 • You were given the opportunity to read this form.
- 272 • All of the information in this form was discussed with you by an investigator or other
- 273 research personnel to your satisfaction.
- 274 • All your questions have been answered to your satisfaction.
- 275 • You were not pressured and you voluntarily agree to take part in this research.

276

277

278

279 _____
Your Name

279 _____
Your Signature

279 _____
Date

280

281

282

283 _____
284 Name of Person Obtaining/
285 Assisting with Consent

283 _____
284 Signature of Person Obtaining/
285 Assisting with Consent

283 _____
Date

286 The **physician investigator's** signature certifies that s/he **personally** provided the study
287 participant with a description of the study, study procedures, risks, benefits and alternatives to
288 participation.

289

290

291

292 _____
Name of Investigator

292 _____
Signature of Investigator

292 _____
Date

293

294

295

296

297 Copy of Signed and Dated Consent Form Given to the Subject/Parent/LAR

298

299

300

301 **Optional Teach-Back Questions** – These questions can be asked to help ensure that the patient
302 understands the study.

303 Check this box if these questions were reviewed with the patient.

304 We have gone over a lot of information. I would like to ask you a few questions to make sure I
305 have done a good job explaining the study to you.

306 1. In your own words, please answer these questions about this study:

307 a. Why are we doing this study (what are we trying to learn)?

308 b. What things (including tests and procedures) will you have to do in this study?

309 c. What are some of the risks of being in this study?

310 d. What is the benefit of being in this study?

311 e. How will being in this study be different than usual medical care?

312 f. How long will you be in this study?

313 2. Taking part in this study is voluntary. What does that mean to you?

314 a. If you don't want to be in this study, what are your other choices?

315 b. What will happen if you chose not to be in this study?

316 3. What will we do to make sure your information remains confidential?

317 4. What other questions do you have about this study?

